Application of lactobacillus rhamnosus in preparation of product for improving flora disorder and anxiety-like behavior caused by humid and hot environment
By taking Lactobacillus murine BNCC194688 oral, the problems of bacterial disorders and anxiety-like behaviors in humid and heat environment were solved, and the anxiety behavior and intestinal bacterial disorders were improved due to humid and heat environment were demonstrated, showing non-toxic side effects and long-term survival time The application of probiotics provides an effective intervention strategy in humid and heat environments.
Patent Information
- Application Number
- CN202411460383.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-18
- Publication Date
- 2024-11-29
AI Technical Summary
The pathogenesis of neuropsychiatric disorders caused by humid and heat environments is unclear, there is a lack of effective intervention strategies, and intestinal microbiota disorders are closely related to anxiety-like behaviors, and the existing technology is difficult to effectively solve this problem.
BNCC194688 Lactobacillus murine is used as a probiotic, and is used for 14 consecutive days to improve bacterial disorders and anxiety-like behaviors caused by humid and heat environment. The product can be in drug form, such as tablets, granules, capsules or oral liquids. It also contains pharmaceutically acceptable auxiliary materials, Lactobacillus murine is the only active ingredient.
Oral administration of Lactobacillus murine significantly improves anxiety-like behaviors and intestinal flora disorders caused by humid and heat environment, and has no adverse toxic and side effects. It survives for a long time and reduces environmental pollution. It has a simple way of use.
Smart Images

Figure CN119033828A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine, and in particular relates to an application of Lactobacillus murinus in the preparation of a product for improving flora disorder and anxiety-like behavior caused by a hot and humid environment. Background Art
[0002] Climate factors such as humidity, temperature, and air pressure are significantly correlated with the occurrence of negative emotions such as fatigue syndrome, depression, and anxiety. Previous studies have also found that extreme high temperatures and high humidity can affect emotional and behavioral disorders and increase the number of patients with schizophrenia, mania, and neurological diseases. As the problem of global warming further intensifies, the impact of extreme hot and humid environments on human negative emotions (such as anxiety) will further expand, and the impact of environmental changes on mental health will receive more and more attention. However, the pathogenesis of neuropsychiatric disorders caused by hot and humid environments is still unclear, and there is a lack of corresponding intervention strategies.
[0003] The gut microbiota is an important partner in diseases driven by environmental changes by buffering or exacerbating negative effects on host populations. Environmental temperature changes may reorganize the gut microbiota of wild animals, and microbial responses are involved in many physiological and pathological processes. Our previous studies have shown that the gut microbiota of mice exposed to a hot and humid environment for a long time is ecologically disturbed. There is increasing evidence that some neurological diseases may be attributed to changes in gut microbial diversity. For example, a cafeteria diet leads to downregulation of gut microbiota such as Streptococcus, Lactobacillus, and Butyrivibrio, which is considered to be the cause of memory deficits in rats. It has also been reported that gut microbial correction is a potential mechanism for the efficiency of antidepressant drugs in mouse models. In a clinical trial, fecal microbiota transplantation from a healthy young adult alleviated the patient's anxiety and depressive behaviors. Due to the close relationship between the gut microbiota and neural function, decoding the characteristics of the gut microbiota under specific environmental conditions will help develop therapeutic strategies for neuropsychiatric diseases. Summary of the invention
[0004] The purpose of the present invention is to provide an application of Lactobacillus murinus in the preparation of a product for improving flora disorder and anxiety-like behavior caused by a hot and humid environment.
[0005] Preferably, the Lactobacillus murine is BNCC194688 Lactobacillus murine.
[0006] More preferably, the product is a medicine.
[0007] More preferably, the medicine is at least one of tablets, granules, capsules, and oral liquids.
[0008] More preferably, the medicine further contains pharmaceutically acceptable excipients.
[0009] More preferably, Lactobacillus murinus is the only active ingredient in the medicament.
[0010] Compared with the prior art, the present invention has the following beneficial effects:
[0011] The present invention firstly finds that oral Lactobacillus murinus can be used to treat flora disorders caused by hot and humid environment and improve anxiety-like behaviors. As a probiotic, Lactobacillus murinus is easy to use, has no adverse toxic side effects, can reduce environmental pollution, and has a long survival time. BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Figure 1 These are the results of the open field test and the elevated plus maze test in Example 1.
[0013] Figure 2 These are the test results of the intestinal flora of the NC group, HHE+S group, and HHE+L group in Example 1. DETAILED DESCRIPTION
[0014] Example 1
[0015] Lactobacillus murinus (BNCC194688, BNCC) was purchased from BeNa Culture Collection and was taken orally (suspended in saline) for 10 min per day. 8 colony forming units for 14 consecutive days.
[0016] Morphological characteristics of Lactobacillus murine (BNCC194688, BNCC): colony diameter is 1-2mm, round, with neat edges, opaque, milky white on the front, milky white on the back, convex in the middle, smooth and bright surface, moist texture, easy to pick up, G+ (blue-purple), bacillus.
[0017] Activation steps: ① Prepare a test tube containing 5-10ml liquid culture medium and two plates; ② Open it in the safety cabinet, burn the bottom with an alcohol lamp, then quickly drip sterile water to break it, and then break it with tweezers; ③ Pipette 0.5ml liquid culture medium into the freeze-dried tube, put it back into the liquid test tube after it is fully dissolved, and mix it; ④ Pipette 0.2ml bacterial suspension into the plate, spread it evenly, repeat twice to obtain two plates; ⑤ Culture all the liquid test tubes and plates under the above-mentioned culture conditions until the bacteria grow.
[0018] Modeling method: The modeling mice used were C57BL / 6 mice, 7 weeks old, male mice.
[0019] ① Normal environment group: raised in a normal conventional environment (22-24℃ and 45-55% humidity; NC group) ② Humid heat environment group: raised in a humid heat environment (31-33℃ and 91-95% humidity; HHE group) for 45 days, and tested by open field and elevated plus maze behavioral experiments. If the mice show behavioral abnormalities (i.e., reduced exploration time in the central area of the open field and in the open arms of the elevated plus maze), the model is considered to be successfully established.
[0020] C57BL / 6 mice induced by humid heat environment were randomly divided into two groups. One group was given normal saline by gavage, and the other group was given Lactobacillus murine (10 8 We found that compared with the normal environment mice group (NC group), the mice in the humid heat environment group given normal saline did not improve the anxiety-like behavior of the mice. However, the mice in the humid heat environment group given oral administration of Lactobacillus murine showed a significant improvement in anxiety-like behavior compared with the mice in the humid heat environment group given normal saline (e.g. Figure 1 As shown, mice given Lactobacillus murinus by gavage (HHE+L group) spent more time exploring the center area of the open field (white box area) and the open arms of the elevated plus maze (white dotted area) than mice given normal saline by gavage (HHE+S group). At the same time, we also found that oral administration of Lactobacillus murinus can improve the disturbance of intestinal flora caused by hot and humid environment (such as Figure 2 As shown, compared with the mice in the normal environment group (NC group), the abundance of Frimicutes and Actinobacteriota in mice in the humid heat environment was significantly reduced, while the administration of normal saline did not effectively improve the situation (HHE+S group). However, after oral administration of Lactobacillus murine to mice in the humid heat environment (HHE+L group), the abundance of Frimicutes and Actinobacteriota in mice in the humid heat environment was significantly increased compared with that in mice in the humid heat environment group given normal saline).
[0021] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.
Claims
1. An application of Lactobacillus murineus in the preparation of a product for improving flora disorders and anxiety-like behaviors caused by hot and humid environments.
2. The use according to claim 1, characterized in that: The Lactobacillus ratus is BNCC194688 Lactobacillus ratus.
3. The use according to claim 2, characterized in that: The product described is a drug.
4. The use according to claim 3, characterized in that The medicine is at least one of tablets, granules, capsules and oral liquids.
5. The use according to claim 4, characterized in that: The medicine also contains pharmaceutically acceptable excipients.
6. The use according to any one of claims 3 to 5, characterized in that: Lactobacillus murinus is the only active ingredient in the medicine.
Citation Information
Patent Citations
Application of lactobacillus murinus in preparation of composition for preventing and treating intestinal ischemia reperfusion injury
CN111714524A
Lactobacillus rhamnosus BYU8 as well as fungicide and application thereof
CN116103206A
Application of inactivated lactobacillus muricatum in preparation of medicine for preventing and / or treating dyskinesia
CN117357563A
